Page 90 - Read Online

Lo Re et al. J Cancer Metastasis Treat 2020;6:17 I http://dx.doi.org/10.20517/2394-4722.2020.11 Page 9 of 9

18. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin.
Cancer 1991;67:2030-2.
19. Zhang M, Luo H, Hui L. MiR-3619-5p hampers proliferation and cisplatin resistance in cutaneous squamous-cell carcinoma via KPNA4.
Biochem Biophys Res Commun 2019;513:419-25.
20. Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, et al. Phase II study of single-agent panitumumab in patients with incurable
cutaneous squamous cell carcinoma. Ann Oncol 2014;25:2047-52.
21. Huang GC, Liu SY, Lin MH, Kuo YY, Liu YC. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Jpn J Clin Oncol 2004;34:499-504.
22. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, et al. Induction of thymidine phosphorylase activity and enhancement of
capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.
23. Markham A, Duggan S. Cemiplimab: first global approval. Drugs 2018;78:1841-6.
24. Chen A, Ali N, Boasberg P, Ho AS. Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and
nivolumab. J Clin Med 2018;7:10.
25. Miller DM, Faulkner-Jones BE, Stone JR, Drews RE. Complete pathologic response of metastatic cutaneous squamous cell carcinoma
and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Rep 2017;3:412-5.
26. Blum V, Müller B, Hofer S, Pardo E, Zeidler K, et al. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. Eur J
Dermatol 2018;28:78-81.
27. Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced
cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol 2016;175:1382-6.
28. Pandey A, Liaukovich M, Joshi K, Avezbakiyev BI, O’Donnell JE. Uncommon presentation of metastatic squamous cell carcinoma of the
skin and treatment challenges. Am J Case Rep 2019;20:294-9.
29. Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated,
proof-of-concept study. J Am Acad Dermatol 2019;80:564-6.
30. Tran DC, Colevas AD, Chang AL. Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma. JAMA
Dermatol 2017;153:92-4.
31. Degache E, Crochet J, Simon N, Tardieu M, Trabelsi S, et al. Major response to pembrolizumab in two patients with locally advanced
cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 2018;32:e257-8.
32. Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, et al. Expression of programmed cell death ligand in cutaneous squamous
cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol 2017;153:299-303.
33. Kudchadkar RR, Yushak ML, Lawson DH, Delman KA, Lowe MC, Goings M, et al Phase II trial of pembrolizumab (MK-3475) in
metastatic cutaneous squamous cell carcinoma (cSCC). J Clini Oncol 2018;36:9543.
34. Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, et al. Rapid response of metastatic cutaneous squamous cell carcinoma
to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer 2017;83:99-102.
35. Assam JH, Powell S, Spanos WC. Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing
dramatic response to programmed cell death protein 1 inhibitor therapy. Clin Skin Cancer 2016;1:26-9.
36. Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, et al. Therapy of bovine ocular squamous-cell carcinoma with local doses
of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 1995;41:10-4.
37. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 2000;6
Suppl 1:S2-7.
38. Chinen T, Kannan AK, Levine AG, Fan X, Klein U, et al. An essential role for the IL-2 receptor in T reg cell function. Nat Immunol
2016;17:1322-33.
39. Liao W, Lin JX, Wang L, Li P, Leonard WJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell
lineages. Nat Immunol 2011;12:551-9.
40. Zoso A, Mazza EM, Bicciato S, Mandruzzato S, Bronte V, et al. Human fibrocytic myeloid-derived suppressor cells express IDO and
promote tolerance via Treg-cell expansion. Eur J Immunol 2014;44:3307-19.
41. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different
subsets of myeloid cells. Blood 2011;117:6532-41.
42. Bracho-Sanchez E, Hassanzadeh A, Brusko MA, Wallet MA, Keselowsky BG. Dendritic cells treated with exogenous indoleamine
2,3-dioxygenase maintain an immature phenotype and suppress antigen-specific T cell proliferation. J Immunol Regen Med
2019;5:100015.
43. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. Increased circulating myeloid-derived suppressor cells
correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol
Immunother 2009;58:49-59.
44. Lo Re G, Lo Re F, Doretto P, Del Conte A, Amadio M, et al. Cyclophosphamide with or without fluorouracil followed by subcutaneous or
intravenous interleukin-2 use in solid tumors: a feasibility off-label experience. Cytokine 2019;113:50-60.
45. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, et al. Paclitaxel enhances carboplatin-DNA adduct formation and cytotoxicity. Chem Res
Toxicol 2015;28:2250-2.
46. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, et al. Induction of thymidine phosphorylase activity and enhancement of
capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.